Activated protein C resistance - In the absence of factor V Leiden - And pregnancy

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 2, 2006, Pages 361-366

  Lindqvist, Pelle G ^a,b   Svensson, P ^a   Dahlback B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

APC resistance; Fetal loss; Growth restriction; Leiden; Preeclampsia; Pregnancy complications

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; FETUS; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NEWBORN; OBESITY; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THIRD TRIMESTER PREGNANCY; VENOUS THROMBOEMBOLISM; BLOOD; CASE CONTROL STUDY; FETUS DEATH; GENETICS; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RISK FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; CASE-CONTROL STUDIES; FACTOR V; FEMALE; FETAL DEATH; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MALE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33645578365     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01714.x     Document Type: Article

References (20)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K, Regan L. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-5.
4. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
5. Graf LL, Welsh CH, Qamar Z, Marlar RA. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003; 119: 52-60.
6. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-6.
7. Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 2003; 361: 901-8.
8. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: A meta-analysis. Thromb Haemost 2004; 91: 700-11.
9. Lindqvist PG, Svensson PJ, Dahlbäck B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss -a possible evolutionary selection mechanism. Thromb Haemost 1998; 79: 69-73.
10. Lindqvist PG, Svensson PJ, Marsál K, Grennert L, Lutherkort M, Dahlbäck B. Activated protein C resistance (FV: Q506) and pregnancy. Thromb Haemost 1999; 81: 532-7.
11. Lindqvist PG, Zöller B, Dahlbäck B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of activated protein C resistance (FV Leiden). An evolutionary advantage? Thromb Haemost 2001; 86: 1122-23.
12. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
13. WHO. International Classification of Diseases, 9th Rev. (ICD-9). Geneva: World Health Organisation, 1976.
14. Persson PH, Weldner BM. Intra-uterine weight curves obtained by ultrasound. Acta Obstet Gynecol Scand 1986; 65: 169-73.
15. Clark P, Sattar N, Walker ID, Greer IA. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: Significance of pregnancy associated activated protein C resistance. Thromb Haemost 2001; 85: 30-5.
16. Lindqvist PG, Marsal K. Moderate smoking during pregnancy is associated with a reduced risk of preeclampsia. Acta Obstet Gynecol Scand 1999; 78: 693-7.
17. Lindqvist P, Dahlbäck B, Marsal K. Thrombotic risk during pregnancy: A population study. Obstet Gynecol 1999; 94: 595-9.
18. Clark P, Walker ID, Greer I. Acquired activated protein-C resistance in pregnancy and association with increased thrombin generation and fetal weight. Lancet 1999; 353: 292-3.
19. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995 345: 152-5.
20. Erhardt E, Stankovics J, Molnar D, Adamovich K, Melegh B. High prevalence of factor V Leiden mutation in mothers of premature neonates. Biol Neonate 2000; 78: 145-6.